Inion Oyj - Decisions of general meeting

RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 3 MAY 2007

Inion Oy                                    
                           ('Inion' or the 'Company')                           

            RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 3 MAY 2007            
                                                                                
Tampere, Finland and Takeley, UK. 4 May 2007...Inion Oy (LSE: IIN) announces    
that all resolutions proposed to shareholders at its Annual General Meeting held
yesterday were duly passed.                                                     
                                                                                
The following resolutions were passed at the AGM:                               

I Proposal by the Board to amend the Articles of Association                    
Amendments to the Articles of Association are as follows:                       
3 §: Provision regarding the minimum and maximum share capital shall be removed.
4 §: Provision regarding the nominal value of the shares shall be removed.      
5 §: Provisions regarding the record date shall be removed and content of the   
current provision shall be amended so that it only states that the shares of the
Company belong to the book-entry system.                                        
6 §: Provision regarding the election of Directors and rotation shall be amended
so that each Director is elected annually at the AGM and the term served by the 
Director will end at the end of the subsequent AGM.                             
10 §: Provision regarding the right to sign for the Company shall be amended so 
that the “right to sign” is replaced with “representation” of the company in    
accordance with the Companies Act.                                              

In addition, the numbering of the provisions shall be amended accordingly.      

II Matters belonging to the Annual General Meeting in accordance with 14 § of   
the Articles of Association                                                     

That the annual accounts for the year ended 31 December 2006 be adopted;        
That no dividend be declared in respect of the year 2006;                       
That Directors and the Chief Executive Officer be discharged from liability;    
Number of Directors to be increased to nine (9);                                
Appointment of Göran Ando as Director;                                          
Appointment of James Beery as Director;                                         
Appointment of Julien Cotta as Director;                                        
Appointment of Auvo Kaikkonen as Director;                                      
Appointment of Peter Allen as Director;                                         
Appointment of David Anderson as Director;                                      
Appointment of Peter Jensen as Director;                                        
Appointment of Chris Lee as Director;                                           
Appointment of Markku Silén as Director;                                        
Resolve on the remuneration to the Directors as proposed; and                   
Resolve on the remuneration to the auditors, PricewaterhouseCoopers Oy.         

III Proposals by the Board for authority to the Board of Directors to issue     
shares                                                                          
Authorisations for the Board of Directors to issue shares as follows:           
Authorisation for the Board of Directors to issue no more than 2,843,015 shares 
in respect of the equity-based incentive scheme for Mr Lee;                     
Authorisation for the Board of Directors to issue no more than 3,700,000 shares 
in respect of the 2007 equity-based incentive scheme; and                       
Authorisation for the Board of Directors to issue no more than 370,000 shares in
respect of the remuneration of Non-Executive Directors.                         

The maximum number of shares to be issued under these authorisations will thus  
not exceed 6,913,015 shares.                                                    

                                     -ends-                                     

For further information, please contact:                                        

--------------------------------------------------------------------------------
| Inion Oy	                                 | Tel: +44 1279 874 222            |
| Dr Göran Ando, Chairman                   |                                  |
| Chris Lee, Chief Executive Officer        |                                  |
| Julien Cotta, Chief Financial Officer     |                                  |
| 	                                         |                                  |
--------------------------------------------------------------------------------
| Citigate Dewe Rogerson                    | Tel: +44 207 638 9571            |
| Mark Swallow / David Dible / Helena       |                                  |
| Galilee                                   |                                  |
--------------------------------------------------------------------------------

About Inion                                                                     

Inion Oy is a medical devices company focused on the development and successful 
commercialisation of innovative biodegradable and bioactive implants in key     
target markets. The Company's target segments are Spine and Specialty           
Orthopaedics.                                                                   

Inion's core expertise and technology lies in the design and manufacture of     
innovative biodegradable plates, screws, pins and membranes, which are used to  
enhance the healing of bone or soft tissue injuries to the skeleton, such as    
those caused by trauma or by reconstructive surgery. Inion implants are made    
from its proprietary Inion Optima™ family of biomaterials, with properties      
tailored for specific surgical applications, in terms of strength, flexibility  
and rate of degradation.                                                        
                                                                                
Inion is also focused on developing proprietary new bioactive and biodegradable 
biomaterials that promote bone healing and accelerate patient rehabilitation.   

Inion was incorporated in early 2000 and listed on the Official List of the UK  
Listing Authority in December 2004. The Company has an office and an R&D        
facility in the UK and head office, R&D and production facilities in Tampere,   
Finland.                                                                        

Further information on Inion can be found on the Company's website:             
www.inion.com                                                                   

This announcement includes "forward-looking statements" which include all       
statements other than statements of historical facts, including, without        
limitation, those regarding the Group's financial position, business strategy,  
plans and objectives of management for future operations (including development 
plans and objectives relating to the Group's products), and any statements      
preceded by, followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims", "intends", "will", 
"can", "may", "anticipates", "would", "should", "could" or similar expressions  
or the negative thereof. Such forward-looking statements involve known and      
unknown risks, uncertainties and other important factors beyond the Group's     
control that could cause the actual results, performance or achievements of the 
Group to be materially different from future results, performance or            
achievements expressed or implied by such forward-looking statements. Such      
forward-looking statements are based on numerous assumptions regarding the      
Group's present and future business strategies and the environment in which the 
Group will operate in the future. Among the important factors that could cause  
the Group's actual results, performance or achievements to differ materially    
from those in forward-looking statements include those relating to Inion's      
funding requirements, regulatory approvals, reliance on third parties,          
intellectual property, key personnel and other factors. These forward-looking   
statements speak only as at the date of this announcement. The Group expressly  
disclaims any obligation or undertaking to disseminate any updates or revisions 
to any forward-looking statements contained in this announcement to reflect any 
change in the Group's expectations with regard thereto or any change in events, 
conditions or circumstances on which any such statements are based. As a result 
of these factors, prospective investors are cautioned not to rely on any        
forward-looking statement.